Palisade Bio (PALI) announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board, CAB. Palisade plans to submit an Investigational New Drug application for a Phase 2 study of PALI-2108 in UC in the first half of 2026, with parallel development planning underway in FSCD.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: